Search results for 785

Brilliant Violet 785 anti-human CD80 Antibody anti-CD80 - 2D10, BioLegend, 305237
Additional reported applications (for the relevant formats) include:in vitroblocking of T cell activation, immunohistochemical staining of acetone-fixed frozen tissue sections2, immunoprecipitation, and Western blotting3. The Ultra-LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. Nos. 305245 & 305246).
Host
Mouse
Reactivity
Human
Applications
FC -Quality tested
Conjugation

Brilliant Violet 785 anti-human CD80 Antibody anti-CD80 - 2D10, BioLegend, 305238
Additional reported applications (for the relevant formats) include:in vitroblocking of T cell activation, immunohistochemical staining of acetone-fixed frozen tissue sections2, immunoprecipitation, and Western blotting3. The Ultra-LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. Nos. 305245 & 305246).
Host
Mouse
Reactivity
Human
Applications
FC -Quality tested
Conjugation

Brilliant Violet 785™ anti-mouse CD103 Antibody, CD103, 2E7, BioLegend, 121439
Additional reported applications (for the relevant formats) include: immunoprecipitation1, immunohistochemical staining1,7of acetone-fixed frozen sections, immunofluorescence2, andin vitroactivation1.
Host
Armenian Hamster
Reactivity
Mouse
Applications
FC -Quality tested
Conjugation

Brilliant Violet 785 anti-human CD20 Antibody anti-CD20 - 2H7, BioLegend, 302355
The epitope recognized by clone 2H7 has been mapped to the sequence YNCEPANPSEKNSPST which lies in the large extracellular loop of human CD20. Additional reported applications (for the relevant formats) include: immunoprecipitation4and immunohistochemical staining of acetone-fixed frozen sections5.
Host
Mouse
Reactivity
Human, Cynomolgus, Rhesus
Applications
FC - Quality tested
Conjugation

Brilliant Violet 785 anti-human CD20 Antibody anti-CD20 - 2H7, BioLegend, 302356
The epitope recognized by clone 2H7 has been mapped to the sequence YNCEPANPSEKNSPST which lies in the large extracellular loop of human CD20. Additional reported applications (for the relevant formats) include: immunoprecipitation4and immunohistochemical staining of acetone-fixed frozen sections5.
Host
Mouse
Reactivity
Human, Cynomolgus, Rhesus
Applications
FC - Quality tested
Conjugation

Brilliant Violet 785 anti-human CD11c Antibody anti-CD11c - 3.9, BioLegend, 301643
Clone 3.9 preferentially binds the activated form of CD11c, is specific for the I domain of CD11c, and is able to partially block the binding of CD11c and ICAM-4. 3.9 binding is divalent cation dependent12. While analyzing blood, it is best to use heparin as the anti-coagulant and not EDTA. Since the ability of clone 3.9 to bind to its target is divalent cation dependent, the usage of EDTA as an anti-coagulant may be detrimental to staining due to its chelating properties.Additional reported applications (for the relevant formats) include: immunohistochemical staining of acetone-fixed frozen tissue sections4, and functional assays5,6. The LEAF™purified antibody (Endotoxin <0.1 EU/μg, Azide-Free, 0.2 μm filtered) is recommended for functional assays (Cat. No. 301616). For highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 301632) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin <0.01 EU/µg).
Host
Mouse
Reactivity
Human, Cynomolgus, Rhesus
Applications
FC - Quality tested
Conjugation

Brilliant Violet 785 anti-human CD11c Antibody anti-CD11c - 3.9, BioLegend, 301644
Clone 3.9 preferentially binds the activated form of CD11c, is specific for the I domain of CD11c, and is able to partially block the binding of CD11c and ICAM-4. 3.9 binding is divalent cation dependent12. While analyzing blood, it is best to use heparin as the anti-coagulant and not EDTA. Since the ability of clone 3.9 to bind to its target is divalent cation dependent, the usage of EDTA as an anti-coagulant may be detrimental to staining due to its chelating properties.Additional reported applications (for the relevant formats) include: immunohistochemical staining of acetone-fixed frozen tissue sections4, and functional assays5,6. The LEAF™purified antibody (Endotoxin <0.1 EU/μg, Azide-Free, 0.2 μm filtered) is recommended for functional assays (Cat. No. 301616). For highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 301632) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin <0.01 EU/µg).
Host
Mouse
Reactivity
Human, Cynomolgus, Rhesus
Applications
FC - Quality tested
Conjugation

Brilliant Violet 785™ anti-mouse CD31 Antibody CD31, 390, BioLegend, 102435
Anti-mouse CD31 clones 390 and MEC13.3 bind to their respective non-overlapping epitopes in IgD2 of CD31.8Additional reported applications (for the relevant formats) include: immunoprecipitation1,in vitroandin vivoblocking of CD31-mediated cell-cell interactions1-4, and immunohistochemical staining5,6,7of acetone-fixed frozen sections and zinc-fixed paraffin-embedded sections.Special Note:This antibody is not recommended for formalin-fixed paraffin-embedded sections. The LEAF™ purified antibody (Endotoxin < 0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 102412).
Host
Rat
Reactivity
Mouse
Applications
FC -Quality tested
Conjugation

Brilliant Violet 785™ anti-human CD166 Antibody, CD166, 3A6, BioLegend, 343927
Additional reported applications (for the relevant formats) include: immunohistochemical staining of paraffin-embedded tissue sections and immunofluorescence.1
Host
Mouse
Reactivity
Human
Applications
FC - Quality tested
Conjugation

Brilliant Violet 785™ anti-human CD166 Antibody, CD166, 3A6, BioLegend, 343928
Additional reported applications (for the relevant formats) include: immunohistochemical staining of paraffin-embedded tissue sections and immunofluorescence.1
Host
Mouse
Reactivity
Human
Applications
FC - Quality tested
Conjugation
Please provide the required information below so that we can quickly source your products.
